- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05435014
T-ACE Oil by TAE/TACE in Patients With Hepatocellular Carcinoma
Phase I/II Randomized, Double-Blind, First-in-Human Study of T-ACE Oil by Trans-Catheter Arterial Embolization or ChemoEmbolization (TAE/TACE) in Patients With Hepatocellular Carcinoma
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Subjects with HCC that meet all eligibility criteria will be admitted to hospital, and TAE or TACE treatment are performed during the hospitalization period; after embolization, subjects are observed in the ward for 1 to 7 days, and evaluated by physician before being discharged. Subjects will be followed up for 7 weeks after treatment for safety and efficacy evaluation.
Phase I part:
12 evaluable subjects will be enrolled sequentially in Phase I part. The first 3 subjects will receive TAE treatment (whether or not they are contraindicated to Doxorubicin) and the following 3 subjects (4th to 6th subjects) will receive TACE treatment. The remaining subjects may receive TAE or TACE treatment. Subjects will be enrolled sequentially in Phase I. For the first six subjects in Phase I, after the subject completes TAE or TACE treatment and is followed for 2 weeks, safety and tolerability data during this period will be reviewed by the safety review committee (SRC); only approved by the SRC, the next subject may start the TAE or TACE treatment. For the 7th to 12th subjects in Phase I, after the subject completes TAE or TACE treatment and is followed until discharge from hospitalization, safety and tolerability data during this period will be reviewed by the safety review committee (SRC); only approved by the SRC, the next subject may start the TAE or TACE treatment. After data for all 12 evaluable subjects are reviewed by SRC and approval is given by the SRC, the study may proceed to Phase II part.
Phase II part:
70 evaluable subjects will be randomized in a 1:1 ratio to receive TAE/TACE treatment by T-ACE Oil or Lipiodol for safety and efficacy evaluation.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Po-Chin Liang, PI
- Phone Number: 62612 02-23123456
- Email: e510012@yahoo.com.tw
Study Locations
-
-
-
Kaohsiung, Taiwan, 813
- Recruiting
- Kaohsiung Veterans General Hospital
-
Contact:
- Huei-Lung Liang, PI
- Phone Number: 78300 07-3422121
- Email: hlliang@vghks.gov.tw
-
Tainan, Taiwan, 701
- Recruiting
- National Cheng Kung University Hospital
-
Contact:
- Hung-Chih Chiu, PI
- Phone Number: 2682 06-23535355
- Email: toad.chiu@gmail.com
-
Taipei, Taiwan, 100
- Recruiting
- National Taiwan University Hospital
-
Contact:
- Po-Chin Liang, PI
- Phone Number: 62612 02-23123456
- Email: e510012@yahoo.com.tw
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age of over 20 years (or according to local legal definition of majority).
Patients diagnosed of HCC (Meet at least ONE of the following criteria):
- 2-1. Diagnosed via tumor biopsy by pathologists and confirmed by on-service physician.
- 2-2. High risk patients (viral hepatitis B or C or cirrhotic) with typical liver cancer image appeared on MRI or CT scan.
- In very early stage to intermediate stage by BCLC staging (2018 AASLD), HCC tumor numbers ≦ 10, HCC tumor size ≦ 15 centimeters (determined by CT, MRI or ultrasound), with liver function at Child-Pugh score[1] ≦ 8.
- Disease can be treated by trans-arterial chemoembolization, and can be evaluated by Magnetic resonance imaging (MRI), or computed tomography(CT).
- Patients who only require a single TAE/TACE treatment to treat all HCC tumors at once.
- Target HCC tumors should have at least 1 tumor that is larger than 1 cm in diameter (determined by CT, MRI or ultrasound) and non-treated before.
May have received local therapy such as TAE, TACE, radiofrequency ablation(RFA) or surgery and remain eligible for study provided the prior therapy was within the following timeframes and the subject has fully recovered from prior therapy:
- 7-1. TAE/TACE: more than 8 weeks since completion of prior therapy
- 7-2. RFA: After PI confirm subject is fully recovered from prior therapy based on screening visit physical examination and liver function laboratory tests results.
- 7-3. Surgery: After PI confirm subject is fully recovered from prior therapy based on screening visit physical examination and liver function laboratory tests results.
- Patients able to understand, willing to accept and cooperate with all clinical trial practices.
- Willing to sign a written informed consent form
Exclusion Criteria:
- Major branch of portal vein has been invaded by HCC, extrahepatic metastasis or other malignant tumors (current active malignancy or active malignancy within the past 5 years).
- Eligible for curative surgery or transplant as judged by PI.
Evidences of decompensation (Meet at least ONE of the following criteria):
- 3-1. Total Bilirubin > 2 mg/dL
- 3-2. INR > 1.7
- 3-3. Child-Pugh score > 9
- 3-4. refractory ascites
- 3-5. active bleeding
- 3-6. hepatic encephalopathy
- 3-7. severe infection
Any of the following findings (but not limit to):
- 4-1. Heart failure (NYHA Class III or IV), COPD (Stage III or IV)
- 4-2. A marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a QTc interval >480 milliseconds (ms) (CTCAE grade 1) using Fridericia's QT correction formula.
- 4-3. A history of risk factors for torsades de pointes (e.g., heart failure, hypokalemia, family history of Long QT Syndrome) or use of concomitant medications that prolong the QT/QTc interval (e.g., class Ia, Ic or III antiarrhythmic drugs, tricyclic antidepressants or phenothiazines)
- 4-4. Bronchial asthma that may increase the risk associated with study participation, or may interfere with compliance of the protocol as judged by the PI.
- 4-5. Renal dysfunction (eGFR < 60 ml/min/1.73m2 and/or creatinine > 1.5x ULN), or patients is planned to accept any renal replacement therapy during treatment visits.
- 4-6. Diagnosed with hyperthyroidism or receiving treatment for hyperthyroidism. Has unstable thyroid function as judged by the PI (e.g. TSH > 5.0 mIU/L).
- 4-7. Traumatic injuries, clinically significant hemorrhage/bleeding, or clinically significant gastrointestinal bleeding within 8 weeks.
- 4-8. Major cardiovascular disease, including stroke and transient ischemic attack (TIA).
- 4-9. Known homocystinuria.
Any of the following laboratory findings:
- 5-1. WBC < 3000 /μL
- 5-2. Platelets < 100,000/μL
- 5-3. Hgb < 8.5 g/dL
- 5-4. AST > 5x ULN
- 5-5. ALT > 5x ULN
- Performance status Eastern Cooperative Oncology Group (ECOG) of 2 or more.
- Patients whose blood vessel are too difficult to perform TACE procedure as judged by PI.
- TACE procedure would be performed in areas of the liver where bile ducts are dilated as judged by PI.
- Prominent Hepatic arteriovenous (AV) shunt, as judged by PI.
- Non-targeted area may be endangered during TACE procedure, as judged by PI.
- Patients, who have ever accepted TACE therapy, and cannot gain extra benefits from further embolization treatment.
- Number of HCC tumors more than 10.
- Allergy or contraindication to iodine, Lipiodol, allowed contrast agents, allowed Gelfoam suppositories or allowed artery hemostats.
- Pregnant females or lactating females.
- Male or female subjects with fertility who are unwilling to perform highly effective contraception method.
- Subjects who, in the opinion of the investigator, are not suitable to participate in the trial for whatever reason.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: T-ACE Oil
TAE/TACE treatment was performed with T-ACE Oil.
|
TAE/TACE treatment was performed with T-ACE Oil.
The volume of T-ACE Oil injected would be 1-1.5 mL/cm based on the diameter (cm) of the treated tumor.
The maximum dose is 0.25 mL/kg/day but not over 15 mL for each treatment.
|
Active Comparator: Lipiodol
TAE/TACE treatment was performed with Lipiodol.
|
TAE/TACE treatment was performed with Lipiodol.
The volume of Lipiodol injected would be 1-1.5 mL/cm based on the diameter (cm) of the treated tumor.
The maximum dose is 0.25 mL/kg/day but not over 15 mL for each treatment.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Phase I part: Incidence of all adverse events (AEs) after TAE/TACE treatment with T-ACE Oil
Time Frame: 7 weeks after treatment
|
7 weeks after treatment
|
|
Phase I part: Incidence of adverse events of special interest (AESIs) after TAE/TACE treatment with T-ACE Oil
Time Frame: 7 weeks after treatment
|
7 weeks after treatment
|
|
Phase I part: Incidence of all serious adverse events (SAEs) after TAE/TACE treatment with T-ACE Oil
Time Frame: 7 weeks after treatment
|
7 weeks after treatment
|
|
Phase I part: Safety variables evaluation - Blood pressures
Time Frame: Pre-intervention (V1)(-28 to -1 days)
|
Blood pressures (including SBP and DBP, unit: mmHg)of subjects will be measured.
|
Pre-intervention (V1)(-28 to -1 days)
|
Phase I part: Safety variables evaluation - Blood pressures
Time Frame: immediately after the intervention (V2)
|
Blood pressures (including SBP and DBP, unit: mmHg)of subjects will be measured.
|
immediately after the intervention (V2)
|
Phase I part: Safety variables evaluation - Blood pressures
Time Frame: discharge of hospitalization (V2A)(1 to 7 days of discharge of hospitalization)
|
Blood pressures (including SBP and DBP, unit: mmHg)of subjects will be measured.
|
discharge of hospitalization (V2A)(1 to 7 days of discharge of hospitalization)
|
Phase I part: Safety variables evaluation - Blood pressures
Time Frame: 2 weeks after treatment (V3)
|
Blood pressures (including SBP and DBP, unit: mmHg)of subjects will be measured.
|
2 weeks after treatment (V3)
|
Phase I part: Safety variables evaluation - Blood pressures
Time Frame: 6 weeks after treatment (V4)
|
Blood pressures (including SBP and DBP, unit: mmHg)of subjects will be measured.
|
6 weeks after treatment (V4)
|
Phase I part: Safety variables evaluation - Blood pressures
Time Frame: 7 weeks after treatment (V5)
|
Blood pressures (including SBP and DBP, unit: mmHg)of subjects will be measured.
|
7 weeks after treatment (V5)
|
Phase I part: Safety variables evaluation - pulse rate
Time Frame: Pre-intervention (V1)(-28 to -1 days)
|
Pulse rate (beats/min) of subjects will be measured.
|
Pre-intervention (V1)(-28 to -1 days)
|
Phase I part: Safety variables evaluation - pulse rate
Time Frame: immediately after the intervention (V2)
|
Pulse rate (beats/min) of subjects will be measured.
|
immediately after the intervention (V2)
|
Phase I part: Safety variables evaluation - pulse rate
Time Frame: discharge of hospitalization (V2A)(1 to 7 days of discharge of hospitalization)
|
Pulse rate (beats/min) of subjects will be measured.
|
discharge of hospitalization (V2A)(1 to 7 days of discharge of hospitalization)
|
Phase I part: Safety variables evaluation - pulse rate
Time Frame: 2 weeks after treatment (V3)
|
Pulse rate (beats/min) of subjects will be measured.
|
2 weeks after treatment (V3)
|
Phase I part: Safety variables evaluation - pulse rate
Time Frame: 6 weeks after treatment (V4)
|
Pulse rate (beats/min) of subjects will be measured.
|
6 weeks after treatment (V4)
|
Phase I part: Safety variables evaluation - pulse rate
Time Frame: 7 weeks after treatment (V5)
|
Pulse rate (beats/min) of subjects will be measured.
|
7 weeks after treatment (V5)
|
Phase I part: Safety variables evaluation - Body weight.
Time Frame: Pre-intervention (V1)(-28 to -1 days)
|
Body weight (kilograms) of subjects will be measured.
|
Pre-intervention (V1)(-28 to -1 days)
|
Phase I part: Safety variables evaluation - Body weight.
Time Frame: immediately after the intervention (V2)
|
Body weight (kilograms) of subjects will be measured.
|
immediately after the intervention (V2)
|
Phase I part: Safety variables evaluation - Body weight.
Time Frame: discharge of hospitalization (V2A)(1 to 7 days of discharge of hospitalization)
|
Body weight (kilograms) of subjects will be measured.
|
discharge of hospitalization (V2A)(1 to 7 days of discharge of hospitalization)
|
Phase I part: Safety variables evaluation - Body weight.
Time Frame: 2 weeks after treatment (V3)
|
Body weight (kilograms) of subjects will be measured.
|
2 weeks after treatment (V3)
|
Phase I part: Safety variables evaluation - Body weight.
Time Frame: 6 weeks after treatment (V4)
|
Body weight (kilograms) of subjects will be measured.
|
6 weeks after treatment (V4)
|
Phase I part: Safety variables evaluation - Body weight.
Time Frame: 7 weeks after treatment (V5)
|
Body weight (kilograms) of subjects will be measured.
|
7 weeks after treatment (V5)
|
Phase I part: Safety variables evaluation - Respiratory rate
Time Frame: Pre-intervention (V1)(-28 to -1 days)
|
Respiratory rate (times/min) of subjects will be measured.
|
Pre-intervention (V1)(-28 to -1 days)
|
Phase I part: Safety variables evaluation - Respiratory rate
Time Frame: immediately after the intervention (V2)
|
Respiratory rate (times/min) of subjects will be measured.
|
immediately after the intervention (V2)
|
Phase I part: Safety variables evaluation - Respiratory rate
Time Frame: discharge of hospitalization (V2A)(1 to 7 days of discharge of hospitalization)
|
Respiratory rate (times/min) of subjects will be measured.
|
discharge of hospitalization (V2A)(1 to 7 days of discharge of hospitalization)
|
Phase I part: Safety variables evaluation - Respiratory rate
Time Frame: 2 weeks after treatment (V3)
|
Respiratory rate (times/min) of subjects will be measured.
|
2 weeks after treatment (V3)
|
Phase I part: Safety variables evaluation - Respiratory rate
Time Frame: 6 weeks after treatment (V4)
|
Respiratory rate (times/min) of subjects will be measured.
|
6 weeks after treatment (V4)
|
Phase I part: Safety variables evaluation - Respiratory rate
Time Frame: 7 weeks after treatment (V5)
|
Respiratory rate (times/min) of subjects will be measured.
|
7 weeks after treatment (V5)
|
Phase I part: Safety variables evaluation - Body temperature.
Time Frame: Pre-intervention (V1)(-28 to -1 days)
|
Body temperature (oC) of subjects will be measured.
|
Pre-intervention (V1)(-28 to -1 days)
|
Phase I part: Safety variables evaluation - Body temperature.
Time Frame: immediately after the intervention (V2)
|
Body temperature (oC) of subjects will be measured.
|
immediately after the intervention (V2)
|
Phase I part: Safety variables evaluation - Body temperature.
Time Frame: discharge of hospitalization (V2A)(1 to 7 days of discharge of hospitalization)
|
Body temperature (oC) of subjects will be measured.
|
discharge of hospitalization (V2A)(1 to 7 days of discharge of hospitalization)
|
Phase I part: Safety variables evaluation - Body temperature.
Time Frame: 2 weeks after treatment (V3)
|
Body temperature (oC) of subjects will be measured.
|
2 weeks after treatment (V3)
|
Phase I part: Safety variables evaluation - Body temperature.
Time Frame: 6 weeks after treatment (V4)
|
Body temperature (oC) of subjects will be measured.
|
6 weeks after treatment (V4)
|
Phase I part: Safety variables evaluation - Body temperature.
Time Frame: 7 weeks after treatment (V5)
|
Body temperature (oC) of subjects will be measured.
|
7 weeks after treatment (V5)
|
Phase I part: Safety variables evaluation - WBC
Time Frame: Pre-intervention (V1)(-28 to -1 days)
|
WBC (1000/uL) of subjects will be measured.
|
Pre-intervention (V1)(-28 to -1 days)
|
Phase I part: Safety variables evaluation - WBC
Time Frame: immediately after the intervention (V2)
|
WBC (1000/uL) of subjects will be measured.
|
immediately after the intervention (V2)
|
Phase I part: Safety variables evaluation - WBC
Time Frame: discharge of hospitalization (V2A)(1 to 7 days of discharge of hospitalization)
|
WBC (1000/uL) of subjects will be measured.
|
discharge of hospitalization (V2A)(1 to 7 days of discharge of hospitalization)
|
Phase I part: Safety variables evaluation - WBC
Time Frame: 2 weeks after treatment (V3)
|
WBC (1000/uL) of subjects will be measured.
|
2 weeks after treatment (V3)
|
Phase I part: Safety variables evaluation - WBC
Time Frame: 6 weeks after treatment (V4)
|
WBC (1000/uL) of subjects will be measured.
|
6 weeks after treatment (V4)
|
Phase I part: Safety variables evaluation - Platelet count
Time Frame: Pre-intervention (V1)(-28 to -1 days)
|
Platelet count (1000/uL) of subjects will be measured.
|
Pre-intervention (V1)(-28 to -1 days)
|
Phase I part: Safety variables evaluation - Platelet count
Time Frame: immediately after the intervention (V2)
|
Platelet count (1000/uL) of subjects will be measured.
|
immediately after the intervention (V2)
|
Phase I part: Safety variables evaluation - Platelet count
Time Frame: discharge of hospitalization (V2A)(1 to 7 days of discharge of hospitalization)
|
Platelet count (1000/uL) of subjects will be measured.
|
discharge of hospitalization (V2A)(1 to 7 days of discharge of hospitalization)
|
Phase I part: Safety variables evaluation - Platelet count
Time Frame: 2 weeks after treatment (V3)
|
Platelet count (1000/uL) of subjects will be measured.
|
2 weeks after treatment (V3)
|
Phase I part: Safety variables evaluation - Platelet count
Time Frame: 6 weeks after treatment (V4)
|
Platelet count (1000/uL) of subjects will be measured.
|
6 weeks after treatment (V4)
|
Phase I part: Safety variables evaluation - Hb
Time Frame: Pre-intervention (V1)(-28 to -1 days)
|
Hb (g/dL) of subjects will be measured.
|
Pre-intervention (V1)(-28 to -1 days)
|
Phase I part: Safety variables evaluation - Hb
Time Frame: immediately after the intervention (V2)
|
Hb (g/dL) of subjects will be measured.
|
immediately after the intervention (V2)
|
Phase I part: Safety variables evaluation - Hb
Time Frame: discharge of hospitalization (V2A)(1 to 7 days of discharge of hospitalization)
|
Hb (g/dL) of subjects will be measured.
|
discharge of hospitalization (V2A)(1 to 7 days of discharge of hospitalization)
|
Phase I part: Safety variables evaluation - Hb
Time Frame: 2 weeks after treatment (V3)
|
Hb (g/dL) of subjects will be measured.
|
2 weeks after treatment (V3)
|
Phase I part: Safety variables evaluation - Hb
Time Frame: 6 weeks after treatment (V4)
|
Hb (g/dL) of subjects will be measured.
|
6 weeks after treatment (V4)
|
Phase I part: Safety variables evaluation - blood urea nitrogen test
Time Frame: Pre-intervention (V1)(-28 to -1 days)
|
BUN (mg/dL) of subjects will be measured.
|
Pre-intervention (V1)(-28 to -1 days)
|
Phase I part: Safety variables evaluation - blood urea nitrogen test
Time Frame: immediately after the intervention (V2)
|
BUN (mg/dL) of subjects will be measured.
|
immediately after the intervention (V2)
|
Phase I part: Safety variables evaluation - blood urea nitrogen test
Time Frame: discharge of hospitalization (V2A)(1 to 7 days of discharge of hospitalization)
|
BUN (mg/dL) of subjects will be measured.
|
discharge of hospitalization (V2A)(1 to 7 days of discharge of hospitalization)
|
Phase I part: Safety variables evaluation - blood urea nitrogen test
Time Frame: 2 weeks after treatment (V3)
|
BUN (mg/dL) of subjects will be measured.
|
2 weeks after treatment (V3)
|
Phase I part: Safety variables evaluation - blood urea nitrogen test
Time Frame: 6 weeks after treatment (V4)
|
BUN (mg/dL) of subjects will be measured.
|
6 weeks after treatment (V4)
|
Phase I part: Safety variables evaluation - Bilirubin
Time Frame: Pre-intervention (V1)(-28 to -1 days)
|
Bilirubin-T and Bilirubin-D (mg/dL) of subjects will be measured.
|
Pre-intervention (V1)(-28 to -1 days)
|
Phase I part: Safety variables evaluation - Bilirubin
Time Frame: immediately after the intervention (V2)
|
Bilirubin-T and Bilirubin-D (mg/dL) of subjects will be measured.
|
immediately after the intervention (V2)
|
Phase I part: Safety variables evaluation - Bilirubin
Time Frame: discharge of hospitalization (V2A)(1 to 7 days of discharge of hospitalization)
|
Bilirubin-T and Bilirubin-D (mg/dL) of subjects will be measured.
|
discharge of hospitalization (V2A)(1 to 7 days of discharge of hospitalization)
|
Phase I part: Safety variables evaluation - Bilirubin
Time Frame: 2 weeks after treatment (V3)
|
Bilirubin-T and Bilirubin-D (mg/dL) of subjects will be measured.
|
2 weeks after treatment (V3)
|
Phase I part: Safety variables evaluation - Bilirubin
Time Frame: 6 weeks after treatment (V4)
|
Bilirubin-T and Bilirubin-D (mg/dL) of subjects will be measured.
|
6 weeks after treatment (V4)
|
Phase I part: Safety variables evaluation - Renal function
Time Frame: Pre-intervention (V1)(-28 to -1 days)
|
Creatinine (mg/dL) of subjects will be measured.
|
Pre-intervention (V1)(-28 to -1 days)
|
Phase I part: Safety variables evaluation - Renal function
Time Frame: immediately after the intervention (V2)
|
Creatinine (mg/dL) of subjects will be measured.
|
immediately after the intervention (V2)
|
Phase I part: Safety variables evaluation - Renal function
Time Frame: discharge of hospitalization (V2A)(1 to 7 days of discharge of hospitalization)
|
Creatinine (mg/dL) of subjects will be measured.
|
discharge of hospitalization (V2A)(1 to 7 days of discharge of hospitalization)
|
Phase I part: Safety variables evaluation - Renal function
Time Frame: 2 weeks after treatment (V3)
|
Creatinine (mg/dL) of subjects will be measured.
|
2 weeks after treatment (V3)
|
Phase I part: Safety variables evaluation - Renal function
Time Frame: 6 weeks after treatment (V4)
|
Creatinine (mg/dL) of subjects will be measured.
|
6 weeks after treatment (V4)
|
Phase I part: Safety variables evaluation - Liver function
Time Frame: Pre-intervention (V1)(-28 to -1 days)
|
AST and ALT (U/L) of subjects will be measured.
|
Pre-intervention (V1)(-28 to -1 days)
|
Phase I part: Safety variables evaluation - Liver function
Time Frame: immediately after the intervention (V2)
|
AST and ALT (U/L) of subjects will be measured.
|
immediately after the intervention (V2)
|
Phase I part: Safety variables evaluation - Liver function
Time Frame: discharge of hospitalization (V2A)(1 to 7 days of discharge of hospitalization)
|
AST and ALT (U/L) of subjects will be measured.
|
discharge of hospitalization (V2A)(1 to 7 days of discharge of hospitalization)
|
Phase I part: Safety variables evaluation - Liver function
Time Frame: 2 weeks after treatment (V3)
|
AST and ALT (U/L) of subjects will be measured.
|
2 weeks after treatment (V3)
|
Phase I part: Safety variables evaluation - Liver function
Time Frame: 6 weeks after treatment (V4)
|
AST and ALT (U/L) of subjects will be measured.
|
6 weeks after treatment (V4)
|
Phase I part: Safety variables evaluation - Coagulation function
Time Frame: Pre-intervention (V1)(-28 to -1 days)
|
Prothrombin time and APTT (seconds) of subjects will be measured.
|
Pre-intervention (V1)(-28 to -1 days)
|
Phase I part: Safety variables evaluation - Coagulation function
Time Frame: immediately after the intervention (V2)
|
Prothrombin time and APTT (seconds) of subjects will be measured.
|
immediately after the intervention (V2)
|
Phase I part: Safety variables evaluation - Coagulation function
Time Frame: discharge of hospitalization (V2A)(1 to 7 days of discharge of hospitalization)
|
Prothrombin time and APTT (seconds) of subjects will be measured.
|
discharge of hospitalization (V2A)(1 to 7 days of discharge of hospitalization)
|
Phase I part: Safety variables evaluation - Coagulation function
Time Frame: 2 weeks after treatment (V3)
|
Prothrombin time and APTT (seconds) of subjects will be measured.
|
2 weeks after treatment (V3)
|
Phase I part: Safety variables evaluation - Coagulation function
Time Frame: 6 weeks after treatment (V4)
|
Prothrombin time and APTT (seconds) of subjects will be measured.
|
6 weeks after treatment (V4)
|
Phase I part: Safety variables evaluation - Thyroid function (T3)
Time Frame: Pre-intervention (V1)(-28 to -1 days)
|
T3 (ng/dL) of subjects will be measured.
|
Pre-intervention (V1)(-28 to -1 days)
|
Phase I part: Safety variables evaluation - Thyroid function (T3)
Time Frame: 6 weeks after treatment (V4).
|
T3 (ng/dL) of subjects will be measured.
|
6 weeks after treatment (V4).
|
Phase I part: Safety variables evaluation - Thyroid function (Free T4)
Time Frame: Pre-intervention (V1)(-28 to -1 days)
|
T4 (ng/dL) of subjects will be measured.
|
Pre-intervention (V1)(-28 to -1 days)
|
Phase I part: Safety variables evaluation - Thyroid function (Free T4)
Time Frame: 6 weeks after treatment (V4).
|
T4 (ng/dL) of subjects will be measured.
|
6 weeks after treatment (V4).
|
Phase I part: Safety variables evaluation - Thyroid function (TSH)
Time Frame: Pre-intervention (V1)(-28 to -1 days)
|
TSH (uIU/ml) of subjects will be measured.
|
Pre-intervention (V1)(-28 to -1 days)
|
Phase I part: Safety variables evaluation - Thyroid function (TSH)
Time Frame: 6 weeks after treatment (V4).
|
TSH (uIU/ml) of subjects will be measured.
|
6 weeks after treatment (V4).
|
Phase I part: Safety variables evaluation - ECG test
Time Frame: Pre-intervention (V1)(-28 to -1 days)
|
Electrocardiogram (ECG) of subjects will be measured.
The participants with treatment-related adverse events will be assessed by CTCAE v5.0
|
Pre-intervention (V1)(-28 to -1 days)
|
Phase I part: Safety variables evaluation - ECG test
Time Frame: immediately after the intervention (V2)
|
Electrocardiogram (ECG) of subjects will be measured.
The participants with treatment-related adverse events will be assessed by CTCAE v5.0
|
immediately after the intervention (V2)
|
Phase I part: Safety variables evaluation - ECG test
Time Frame: 6 weeks after treatment (V4)
|
Electrocardiogram (ECG) of subjects will be measured.
The participants with treatment-related adverse events will be assessed by CTCAE v5.0
|
6 weeks after treatment (V4)
|
Phase II part: T-ACE Oil or Lipiodol deposition type on CT scan after TAE/TACE treatment.
Time Frame: 72 hours after treatment
|
CT or MRI image should be taken at the screening visit, after the TAE or TACE procedure and visit 4 (6 weeks after TAE or TACE procedure).
No additional contrast will be administered for the CT after TAE or TACE procedure.
V1 and V4 image evaluation will be performed by MRI.
V2 image evaluation method will be performed by CT scan.
If the subject has had an MRI examination within 28 days before TAE/TACE treatment, the V1 MRI can be skipped.
|
72 hours after treatment
|
Phase II part: mRECIST overall response at 6 weeks after TAE/TACE treatment.
Time Frame: 6 weeks after treatment.
|
mRECIST (modified Response Evaluation Criteria in Solid Tumors) overall response and mRECIST target lesion response will be evaluated based on the image taken at the screening visit and at visit 4 (6 weeks after TAE or TACE procedure).
mRECIST overall response for each patient will be categorized: Complete response (CR), Partial response (PR), Stable disease (SD), and Progressive disease (PD).
mRECIST overall response is based on target lesions and non-target lesions responses and appearance of new lesions and/or extra-hepatic disease.
|
6 weeks after treatment.
|
Phase II part: target lesion response at 6 weeks after TAE/TACE treatment.
Time Frame: 6 weeks after treatment.
|
target lesion response will be evaluated based on the image
|
6 weeks after treatment.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Phase I part: T-ACE Oil deposition type on CT scan after TAE/TACE treatment with T-ACE Oil.
Time Frame: 72 hours after treatment
|
CT or MRI image should be taken at the screening visit, after the TAE or TACE procedure and visit 4 (6 weeks after TAE or TACE procedure).
No additional contrast will be administered for the CT after TAE or TACE procedure.
V1 and V4 image evaluation will be performed by MRI.
V2 image evaluation method will be performed by CT scan.
If the subject has had an MRI examination within 28 days before TAE/TACE treatment, the V1 MRI can be skipped.
|
72 hours after treatment
|
Phase I part: mRECIST overall response at 6 weeks after TAE/TACE treatment with T-ACE Oil.
Time Frame: 6 weeks after treatment.
|
mRECIST (modified Response Evaluation Criteria in Solid Tumors) overall response and mRECIST target lesion response will be evaluated based on the image taken at the screening visit and at visit 4 (6 weeks after TAE or TACE procedure).
mRECIST overall response for each patient will be categorized: Complete response (CR), Partial response (PR), Stable disease (SD), and Progressive disease (PD).
mRECIST overall response is based on target lesions and non-target lesions responses and appearance of new lesions and/or extra-hepatic disease.
|
6 weeks after treatment.
|
Phase I part: target lesion response at 6 weeks after TAE/TACE treatment with T-ACE Oil.
Time Frame: 6 weeks after treatment.
|
target lesion response will be evaluated based on the image
|
6 weeks after treatment.
|
Phase II part: Incidence of all adverse events (AEs) after TAE/TACE treatment with T-ACE Oil or Lipiodol.
Time Frame: 7 weeks after treatment
|
7 weeks after treatment
|
|
Phase II part: Incidence of adverse events of special interest (AESIs) after TAE/TACE treatment with T-ACE Oil or Lipiodol.
Time Frame: 7 weeks after treatment
|
7 weeks after treatment
|
|
Phase II part: Incidence of all serious adverse events (SAEs) after TAE/TACE treatment with T-ACE Oil or Lipiodol.
Time Frame: 7 weeks after treatment
|
7 weeks after treatment
|
|
Phase II part: Safety variables evaluation - Blood pressures
Time Frame: Pre-intervention (V1)(-28 to -1 days)
|
Blood pressures (including SBP and DBP, unit: mmHg) of subjects will be measured.
|
Pre-intervention (V1)(-28 to -1 days)
|
Phase II part: Safety variables evaluation - Blood pressures
Time Frame: immediately after the intervention (V2)
|
Blood pressures (including SBP and DBP, unit: mmHg) of subjects will be measured.
|
immediately after the intervention (V2)
|
Phase II part: Safety variables evaluation - Blood pressures
Time Frame: discharge of hospitalization (V2A)(1 to 7 days of discharge of hospitalization)
|
Blood pressures (including SBP and DBP, unit: mmHg) of subjects will be measured.
|
discharge of hospitalization (V2A)(1 to 7 days of discharge of hospitalization)
|
Phase II part: Safety variables evaluation - Blood pressures
Time Frame: 2 weeks after treatment (V3)
|
Blood pressures (including SBP and DBP, unit: mmHg) of subjects will be measured.
|
2 weeks after treatment (V3)
|
Phase II part: Safety variables evaluation - Blood pressures
Time Frame: 6 weeks after treatment (V4)
|
Blood pressures (including SBP and DBP, unit: mmHg) of subjects will be measured.
|
6 weeks after treatment (V4)
|
Phase II part: Safety variables evaluation - Blood pressures
Time Frame: 7 weeks after treatment (V5)
|
Blood pressures (including SBP and DBP, unit: mmHg) of subjects will be measured.
|
7 weeks after treatment (V5)
|
Phase II part: Safety variables evaluation - Pulse rate
Time Frame: Pre-intervention (V1)(-28 to -1 days)
|
Pulse rate (beats/min) of subjects will be measured.
|
Pre-intervention (V1)(-28 to -1 days)
|
Phase II part: Safety variables evaluation - Pulse rate
Time Frame: immediately after the intervention (V2)
|
Pulse rate (beats/min) of subjects will be measured.
|
immediately after the intervention (V2)
|
Phase II part: Safety variables evaluation - Pulse rate
Time Frame: discharge of hospitalization (V2A)(1 to 7 days of discharge of hospitalization)
|
Pulse rate (beats/min) of subjects will be measured.
|
discharge of hospitalization (V2A)(1 to 7 days of discharge of hospitalization)
|
Phase II part: Safety variables evaluation - Pulse rate
Time Frame: 2 weeks after treatment (V3)
|
Pulse rate (beats/min) of subjects will be measured.
|
2 weeks after treatment (V3)
|
Phase II part: Safety variables evaluation - Pulse rate
Time Frame: 6 weeks after treatment (V4)
|
Pulse rate (beats/min) of subjects will be measured.
|
6 weeks after treatment (V4)
|
Phase II part: Safety variables evaluation - Pulse rate
Time Frame: 7 weeks after treatment (V5)
|
Pulse rate (beats/min) of subjects will be measured.
|
7 weeks after treatment (V5)
|
Phase II part: Safety variables evaluation - Body weight.
Time Frame: Pre-intervention (V1)(-28 to -1 days)
|
Body weight (kilograms) of subjects will be measured.
|
Pre-intervention (V1)(-28 to -1 days)
|
Phase II part: Safety variables evaluation - Body weight.
Time Frame: immediately after the intervention (V2)
|
Body weight (kilograms) of subjects will be measured.
|
immediately after the intervention (V2)
|
Phase II part: Safety variables evaluation - Body weight.
Time Frame: discharge of hospitalization (V2A)(1 to 7 days of discharge of hospitalization)
|
Body weight (kilograms) of subjects will be measured.
|
discharge of hospitalization (V2A)(1 to 7 days of discharge of hospitalization)
|
Phase II part: Safety variables evaluation - Body weight.
Time Frame: 2 weeks after treatment (V3)
|
Body weight (kilograms) of subjects will be measured.
|
2 weeks after treatment (V3)
|
Phase II part: Safety variables evaluation - Body weight.
Time Frame: 6 weeks after treatment (V4)
|
Body weight (kilograms) of subjects will be measured.
|
6 weeks after treatment (V4)
|
Phase II part: Safety variables evaluation - Body weight.
Time Frame: 7 weeks after treatment (V5)
|
Body weight (kilograms) of subjects will be measured.
|
7 weeks after treatment (V5)
|
Phase II part: Safety variables evaluation - Body temperature.
Time Frame: Pre-intervention (V1)(-28 to -1 days)
|
Body temperature (oC) of subjects will be measured.
|
Pre-intervention (V1)(-28 to -1 days)
|
Phase II part: Safety variables evaluation - Body temperature.
Time Frame: immediately after the intervention (V2)
|
Body temperature (oC) of subjects will be measured.
|
immediately after the intervention (V2)
|
Phase II part: Safety variables evaluation - Body temperature.
Time Frame: discharge of hospitalization (V2A)(1 to 7 days of discharge of hospitalization)
|
Body temperature (oC) of subjects will be measured.
|
discharge of hospitalization (V2A)(1 to 7 days of discharge of hospitalization)
|
Phase II part: Safety variables evaluation - Body temperature.
Time Frame: 2 weeks after treatment (V3)
|
Body temperature (oC) of subjects will be measured.
|
2 weeks after treatment (V3)
|
Phase II part: Safety variables evaluation - Body temperature.
Time Frame: 6 weeks after treatment (V4)
|
Body temperature (oC) of subjects will be measured.
|
6 weeks after treatment (V4)
|
Phase II part: Safety variables evaluation - Body temperature.
Time Frame: 7 weeks after treatment (V5)
|
Body temperature (oC) of subjects will be measured.
|
7 weeks after treatment (V5)
|
Phase II part: Safety variables evaluation - WBC
Time Frame: Pre-intervention (V1)(-28 to -1 days)
|
WBC (1000/uL) of subjects will be measured.
|
Pre-intervention (V1)(-28 to -1 days)
|
Phase II part: Safety variables evaluation - WBC
Time Frame: immediately after the intervention (V2)
|
WBC (1000/uL) of subjects will be measured.
|
immediately after the intervention (V2)
|
Phase II part: Safety variables evaluation - WBC
Time Frame: discharge of hospitalization (V2A)(1 to 7 days of discharge of hospitalization)
|
WBC (1000/uL) of subjects will be measured.
|
discharge of hospitalization (V2A)(1 to 7 days of discharge of hospitalization)
|
Phase II part: Safety variables evaluation - WBC
Time Frame: 2 weeks after treatment (V3)
|
WBC (1000/uL) of subjects will be measured.
|
2 weeks after treatment (V3)
|
Phase II part: Safety variables evaluation - WBC
Time Frame: 6 weeks after treatment (V4)
|
WBC (1000/uL) of subjects will be measured.
|
6 weeks after treatment (V4)
|
Phase II part: Safety variables evaluation - Platelet count
Time Frame: Pre-intervention (V1)(-28 to -1 days)
|
Platelet count (1000/uL) of subjects will be measured.
|
Pre-intervention (V1)(-28 to -1 days)
|
Phase II part: Safety variables evaluation - Platelet count
Time Frame: immediately after the intervention (V2)
|
Platelet count (1000/uL) of subjects will be measured.
|
immediately after the intervention (V2)
|
Phase II part: Safety variables evaluation - Platelet count
Time Frame: discharge of hospitalization (V2A)(1 to 7 days of discharge of hospitalization)
|
Platelet count (1000/uL) of subjects will be measured.
|
discharge of hospitalization (V2A)(1 to 7 days of discharge of hospitalization)
|
Phase II part: Safety variables evaluation - Platelet count
Time Frame: 2 weeks after treatment (V3)
|
Platelet count (1000/uL) of subjects will be measured.
|
2 weeks after treatment (V3)
|
Phase II part: Safety variables evaluation - Platelet count
Time Frame: 6 weeks after treatment (V4)
|
Platelet count (1000/uL) of subjects will be measured.
|
6 weeks after treatment (V4)
|
Phase II part: Safety variables evaluation - Hb
Time Frame: Pre-intervention (V1)(-28 to -1 days)
|
Hb (g/dL) of subjects will be measured.
|
Pre-intervention (V1)(-28 to -1 days)
|
Phase II part: Safety variables evaluation - Hb
Time Frame: immediately after the intervention (V2)
|
Hb (g/dL) of subjects will be measured.
|
immediately after the intervention (V2)
|
Phase II part: Safety variables evaluation - Hb
Time Frame: discharge of hospitalization (V2A)(1 to 7 days of discharge of hospitalization)
|
Hb (g/dL) of subjects will be measured.
|
discharge of hospitalization (V2A)(1 to 7 days of discharge of hospitalization)
|
Phase II part: Safety variables evaluation - Hb
Time Frame: 2 weeks after treatment (V3)
|
Hb (g/dL) of subjects will be measured.
|
2 weeks after treatment (V3)
|
Phase II part: Safety variables evaluation - Hb
Time Frame: 6 weeks after treatment (V4)
|
Hb (g/dL) of subjects will be measured.
|
6 weeks after treatment (V4)
|
Phase II part: Safety variables evaluation - blood urea nitrogen test
Time Frame: Pre-intervention (V1)(-28 to -1 days)
|
BUN (mg/dL) of subjects will be measured.
|
Pre-intervention (V1)(-28 to -1 days)
|
Phase II part: Safety variables evaluation - blood urea nitrogen test
Time Frame: immediately after the intervention (V2)
|
BUN (mg/dL) of subjects will be measured.
|
immediately after the intervention (V2)
|
Phase II part: Safety variables evaluation - blood urea nitrogen test
Time Frame: discharge of hospitalization (V2A)(1 to 7 days of discharge of hospitalization)
|
BUN (mg/dL) of subjects will be measured.
|
discharge of hospitalization (V2A)(1 to 7 days of discharge of hospitalization)
|
Phase II part: Safety variables evaluation - blood urea nitrogen test
Time Frame: 2 weeks after treatment (V3)
|
BUN (mg/dL) of subjects will be measured.
|
2 weeks after treatment (V3)
|
Phase II part: Safety variables evaluation - blood urea nitrogen test
Time Frame: 6 weeks after treatment (V4)
|
BUN (mg/dL) of subjects will be measured.
|
6 weeks after treatment (V4)
|
Phase II part: Safety variables evaluation - Bilirubin
Time Frame: Pre-intervention (V1)(-28 to -1 days)
|
Bilirubin-T and Bilirubin-D (mg/dL) of subjects will be measured.
|
Pre-intervention (V1)(-28 to -1 days)
|
Phase II part: Safety variables evaluation - Bilirubin
Time Frame: immediately after the intervention (V2)
|
Bilirubin-T and Bilirubin-D (mg/dL) of subjects will be measured.
|
immediately after the intervention (V2)
|
Phase II part: Safety variables evaluation - Bilirubin
Time Frame: discharge of hospitalization (V2A)(1 to 7 days of discharge of hospitalization)
|
Bilirubin-T and Bilirubin-D (mg/dL) of subjects will be measured.
|
discharge of hospitalization (V2A)(1 to 7 days of discharge of hospitalization)
|
Phase II part: Safety variables evaluation - Bilirubin
Time Frame: 2 weeks after treatment (V3)
|
Bilirubin-T and Bilirubin-D (mg/dL) of subjects will be measured.
|
2 weeks after treatment (V3)
|
Phase II part: Safety variables evaluation - Bilirubin
Time Frame: 6 weeks after treatment (V4)
|
Bilirubin-T and Bilirubin-D (mg/dL) of subjects will be measured.
|
6 weeks after treatment (V4)
|
Phase II part: Safety variables evaluation - Renal function
Time Frame: Pre-intervention (V1)(-28 to -1 days)
|
Creatinine (mg/dL) of subjects will be measured.
|
Pre-intervention (V1)(-28 to -1 days)
|
Phase II part: Safety variables evaluation - Renal function
Time Frame: immediately after the intervention (V2)
|
Creatinine (mg/dL) of subjects will be measured.
|
immediately after the intervention (V2)
|
Phase II part: Safety variables evaluation - Renal function
Time Frame: discharge of hospitalization (V2A)(1 to 7 days of discharge of hospitalization)
|
Creatinine (mg/dL) of subjects will be measured.
|
discharge of hospitalization (V2A)(1 to 7 days of discharge of hospitalization)
|
Phase II part: Safety variables evaluation - Renal function
Time Frame: 2 weeks after treatment (V3)
|
Creatinine (mg/dL) of subjects will be measured.
|
2 weeks after treatment (V3)
|
Phase II part: Safety variables evaluation - Renal function
Time Frame: 6 weeks after treatment (V4)
|
Creatinine (mg/dL) of subjects will be measured.
|
6 weeks after treatment (V4)
|
Phase II part: Safety variables evaluation - Liver function
Time Frame: Pre-intervention (V1)(-28 to -1 days)
|
AST and ALT (U/L) of subjects will be measured.
|
Pre-intervention (V1)(-28 to -1 days)
|
Phase II part: Safety variables evaluation - Liver function
Time Frame: 6 weeks after treatment (V4)
|
AST and ALT (U/L) of subjects will be measured.
|
6 weeks after treatment (V4)
|
Phase II part: Safety variables evaluation - Coagulation function
Time Frame: Pre-intervention (V1)(-28 to -1 days)
|
Prothrombin time and APTT (seconds) of subjects will be measured.
|
Pre-intervention (V1)(-28 to -1 days)
|
Phase II part: Safety variables evaluation - Coagulation function
Time Frame: immediately after the intervention (V2)
|
Prothrombin time and APTT (seconds) of subjects will be measured.
|
immediately after the intervention (V2)
|
Phase II part: Safety variables evaluation - Coagulation function
Time Frame: discharge of hospitalization (V2A)(1 to 7 days of discharge of hospitalization)
|
Prothrombin time and APTT (seconds) of subjects will be measured.
|
discharge of hospitalization (V2A)(1 to 7 days of discharge of hospitalization)
|
Phase II part: Safety variables evaluation - Coagulation function
Time Frame: 2 weeks after treatment (V3)
|
Prothrombin time and APTT (seconds) of subjects will be measured.
|
2 weeks after treatment (V3)
|
Phase II part: Safety variables evaluation - Coagulation function
Time Frame: 6 weeks after treatment (V4)
|
Prothrombin time and APTT (seconds) of subjects will be measured.
|
6 weeks after treatment (V4)
|
Phase II part: Safety variables evaluation - Thyroid function (T3)
Time Frame: Pre-intervention (V1)(-28 to -1 days)
|
T3 (ng/dL) of subjects will be measured.
|
Pre-intervention (V1)(-28 to -1 days)
|
Phase II part: Safety variables evaluation - Thyroid function (T3)
Time Frame: 6 weeks after treatment (V4)
|
T3 (ng/dL) of subjects will be measured.
|
6 weeks after treatment (V4)
|
Phase II part: Safety variables evaluation - Thyroid function (Free T4)
Time Frame: Pre-intervention (V1)(-28 to -1 days)
|
T4 (ng/dL) of subjects will be measured.
|
Pre-intervention (V1)(-28 to -1 days)
|
Phase II part: Safety variables evaluation - Thyroid function (Free T4)
Time Frame: 6 weeks after treatment (V4)
|
T4 (ng/dL) of subjects will be measured.
|
6 weeks after treatment (V4)
|
Phase II part: Safety variables evaluation - Thyroid function (TSH)
Time Frame: Pre-intervention (V1)(-28 to -1 days)
|
TSH (uIU/ml) of subjects will be measured.
|
Pre-intervention (V1)(-28 to -1 days)
|
Phase II part: Safety variables evaluation - Thyroid function (TSH)
Time Frame: 6 weeks after treatment (V4)
|
TSH (uIU/ml) of subjects will be measured.
|
6 weeks after treatment (V4)
|
Phase II part: Safety variables evaluation - ECG test
Time Frame: Pre-intervention (V1)(-28 to -1 days)
|
each component of Electrocardiogram (ECG) of subjects will be measured.
The participants with treatment-related adverse events will be assessed by CTCAE v5.0
|
Pre-intervention (V1)(-28 to -1 days)
|
Phase II part: Safety variables evaluation - ECG test
Time Frame: immediately after the intervention (V2)
|
each component of Electrocardiogram (ECG) of subjects will be measured.
The participants with treatment-related adverse events will be assessed by CTCAE v5.0
|
immediately after the intervention (V2)
|
Phase II part: Safety variables evaluation - ECG test
Time Frame: 6 weeks after treatment (V4)
|
each component of Electrocardiogram (ECG) of subjects will be measured.
The participants with treatment-related adverse events will be assessed by CTCAE v5.0
|
6 weeks after treatment (V4)
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Po-Chin Liang, PI
Publications and helpful links
General Publications
- Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010 Feb;30(1):52-60. doi: 10.1055/s-0030-1247132. Epub 2010 Feb 19.
- Miyayama S, Yamashiro M, Okuda M, Yoshie Y, Sugimori N, Igarashi S, Nakashima Y, Notsumata K, Toya D, Tanaka N, Mitsui T, Matsui O. Chemoembolization for the treatment of large hepatocellular carcinoma. J Vasc Interv Radiol. 2010 Aug;21(8):1226-34. doi: 10.1016/j.jvir.2010.04.015. Epub 2010 Jul 3.
- Lencioni R, de Baere T, Soulen MC, Rilling WS, Geschwind JF. Lipiodol transarterial chemoembolization for hepatocellular carcinoma: A systematic review of efficacy and safety data. Hepatology. 2016 Jul;64(1):106-16. doi: 10.1002/hep.28453. Epub 2016 Mar 7.
- Wang Z, Lin M, Lesage D, Chen R, Chapiro J, Gu T, Tacher V, Duran R, Geschwind JF. Three-dimensional evaluation of lipiodol retention in HCC after chemoembolization: a quantitative comparison between CBCT and MDCT. Acad Radiol. 2014 Mar;21(3):393-9. doi: 10.1016/j.acra.2013.11.006.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- TACE-OHEP-001
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hepatocellular Carcinoma
-
Roswell Park Cancer InstituteNational Comprehensive Cancer NetworkCompletedAdvanced Adult Hepatocellular Carcinoma | Localized Non-Resectable Adult Hepatocellular Carcinoma | Stage IIIA Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma | Stage IIIC Hepatocellular Carcinoma | Stage IVA Hepatocellular Carcinoma | Stage IVB Hepatocellular Carcinoma | Stage III... and other conditionsUnited States
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)RecruitingUnresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | BCLC Stage B Hepatocellular Carcinoma and other conditionsUnited States
-
Roswell Park Cancer InstituteMerck Sharp & Dohme LLCActive, not recruitingAdvanced Adult Hepatocellular Carcinoma | Child-Pugh Class A | Stage III Hepatocellular Carcinoma | Stage IIIA Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma | Stage IIIC Hepatocellular Carcinoma | Stage IV Hepatocellular Carcinoma | Stage IVA Hepatocellular Carcinoma | Stage IVB Hepatocellular...United States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedUnresectable Hepatocellular Carcinoma | Advanced Adult Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma AJCC v7 | Stage IIIC Hepatocellular Carcinoma AJCC v7 | BCLC Stage C Hepatocellular Carcinoma | Stage IV Hepatocellular Carcinoma AJCC v7 | Stage III Hepatocellular Carcinoma AJCC... and other conditionsUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingUnresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | BCLC Stage B Hepatocellular Carcinoma and other conditionsUnited States
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI); Genentech, Inc.RecruitingUnresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | Stage IIIB Hepatocellular Carcinoma... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedUnresectable Hepatocellular Carcinoma | Advanced Adult Hepatocellular Carcinoma | Recurrent Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma AJCC v7 | Stage IIIC Hepatocellular Carcinoma AJCC v7 | Stage IV Hepatocellular Carcinoma AJCC v7 | Stage III Hepatocellular Carcinoma AJCC v7 and other conditionsUnited States, Canada, Puerto Rico
-
Edward KimBristol-Myers Squibb; National Cancer Institute (NCI)TerminatedUnresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | Stage IIIB Hepatocellular Carcinoma... and other conditionsUnited States
-
Mayo ClinicNational Cancer Institute (NCI)RecruitingAdvanced Hepatocellular Carcinoma | BCLC Stage B Hepatocellular Carcinoma | BCLC Stage C Hepatocellular Carcinoma | Metastatic Hepatocellular Carcinoma | BCLC Stage A Hepatocellular CarcinomaUnited States
-
Northwestern UniversityBristol-Myers Squibb; National Cancer Institute (NCI)CompletedStage IIIA Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma | Stage IIIC Hepatocellular Carcinoma | Stage IVA Hepatocellular Carcinoma | Stage IVB Hepatocellular CarcinomaUnited States
Clinical Trials on T-ACE Oil
-
CelgeneTerminatedBeta Thalassemia Intermedia | Beta Thalassemia MajorFrance, United Kingdom, Italy, Greece
-
Ace Cells Lab LimitedUnknownPsoriasis | Atopic Dermatitis | Chronic EczemaSerbia, United Kingdom
-
Acceleron Pharma Inc. (a wholly owned subsidiary...TerminatedFacioscapulohumeral Muscular DystrophyUnited States, Spain, Canada
-
University of Alabama at BirminghamACE Surgical Supply, Inc.Completed
-
Megadyne Medical Products Inc.UnknownAbdominoplasty | Bilateral Breast Reduction | Bilateral Breast Lift | Bilateral Brachioplasty | Bilateral Lateral Thigh and Buttocks LiftUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedSotatercept in Treating Patients With Myeloproliferative Neoplasm-Associated Myelofibrosis or AnemiaAnemia | Myelofibrosis | Myelodysplastic/Myeloproliferative NeoplasmUnited States
-
University of AlbertaCompletedCoronary Artery DiseaseCanada
-
Acceleron Pharma Inc. (a wholly owned subsidiary...Completed
-
Acceleron Pharma Inc. (a wholly owned subsidiary...CompletedMultiple Myeloma | Advanced Solid TumorsUnited States
-
University Hospital, GrenobleNot yet recruitingChild Abuse | Child Development | Health Behavior | Infertility, Female | Trauma, Psychological